Even very low THC doses can trigger positive workplace urine tests, and regular users may test positive for weeks after quitting — raising questions about whether current testing thresholds actually measure impairment.
Anyone subject to cannabis urine testing, employers setting drug testing policies, forensic toxicologists, legal professionals dealing with cannabis detection cases.
What the researchers found
This systematic review synthesized 92 studies examining urinary THC and THC-metabolite concentrations across different cannabis use patterns and testing contexts.
The findings exposed major problems with current testing thresholds. At the standard workplace threshold (15 ng/mL total 11-COOH-THC), even low single doses (1.0–5.0 mg THC) and very low repeated doses (<1.0 mg/day) were sometimes sufficient to trigger a positive result — particularly with oral ingestion. Weekly to daily cannabis users could test positive for extended periods after quitting.
The review contextualized these laboratory findings against the thresholds used in two key settings: workplaces (and aligned contexts like criminal justice) and competitive sport. The disconnect between what triggers a positive test and what indicates recent use or impairment was a central theme.
The review also examined how different cannabis products (smoked, vaped, oral) and dosing patterns affect urinary metabolite concentrations over time, providing the most comprehensive mapping to date of the relationship between cannabis use and urine test results.
Why it matters
Urine testing is the most common form of cannabis detection in workplaces, criminal justice, and sport — affecting millions of people. This systematic review demonstrates that current thresholds often detect past use rather than recent consumption or impairment. For regular users trying to quit, weeks of positive tests create legal and employment consequences disconnected from their actual cannabis status.
The numbers in context
92 studies reviewed. Workplace threshold: 15 ng/mL total 11-COOH-THC. Single doses as low as 1.0–5.0 mg THC could exceed workplace threshold. Oral ingestion more likely to trigger positive results than inhalation at equivalent doses. Weekly-to-daily users could test positive for extended periods after cessation.
How the study worked
Systematic review identifying 92 eligible studies. Analyzed urinary concentrations of THC and THC metabolites (primarily 11-COOH-THC) following controlled cannabis/cannabinoid administration (acute and repeated dosing) and in cannabis users (during active use and extended abstinence). Results contextualized against workplace (15 ng/mL) and sport testing thresholds.
Who was studied
92 studies on urinary THC and metabolites from various cannabis use patterns.
What this study cannot tell us
Synthesized studies with varying designs, populations, and analytical methods. Controlled dosing studies use standardized cannabis that may not reflect the potency of commercial products. Individual variation in THC metabolism (influenced by body composition, genetics, and frequency of use) means no single elimination timeline applies to everyone.
How to read the evidence
Systematic review synthesizing 92 studies — strong evidence for the pharmacokinetic patterns, though individual variation limits precision of any specific detection timeline.
When this study was published
Published in 2026, providing the most current comprehensive review of cannabis urine detection data including modern high-potency products.
The bigger picture
This review connects to the driving impairment literature (RTHC-00159, RTHC-00171, RTHC-00266) and the workplace testing research (RTHC-00188) by highlighting a fundamental problem: urine testing measures past exposure, not current impairment. As more jurisdictions legalize cannabis, the gap between what a positive urine test means and what employers, courts, and sporting bodies assume it means becomes a policy issue with real consequences for millions of people.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Should workplace cannabis testing thresholds be raised to better distinguish recent use from distant exposure? Would oral fluid (saliva) or blood testing provide a more meaningful measure of recent cannabis use? How should testing policies adapt as cannabis legalization expands?
Read the original research
Urinary Δ9-tetrahydrocannabinol and metabolite concentrations following cannabis use: A systematic review.
Pharmacological research, 108142
Pharmacological Research is a reputable journal focusing on drug research and pharmacology.
Citation
McCartney, Danielle; Irwin, Christopher; Arnold, Jonathon C; Gordon, Rebecca; McLachlan, Andrew J; McGregor, Iain S. (2026). Urinary Δ9-tetrahydrocannabinol and metabolite concentrations following cannabis use: A systematic review.. Pharmacological research, 108142. https://doi.org/10.1016/j.phrs.2026.108142
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk